

# Comments on *Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version)*

Weiping Liu, Jun Zhu

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

Correspondence to: Jun Zhu. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: zhu-jun2017@outlook.com.

Submitted Sep 16, 2019. Accepted for publication Sep 30, 2019.

doi: 10.21147/j.issn.1000-9604.2019.05.02

View this article at: <https://doi.org/10.21147/j.issn.1000-9604.2019.05.02>

Lymphoid and myeloid neoplasms are common malignant tumors in China, which threaten people's health (1). To improve the diagnosis and treatment of lymphoma, the National Health Commission of the People's Republic of China revised *Chinese guidelines for diagnosis and treatment of malignant lymphoma* in 2018 (2).

The new guidelines are based on the *Classification of Tumours of Haematopoietic and Lymphoid Tissues* revised by the World Health Organization in 2016. The new edition provided principles of accurate pathological diagnosis of lymphoma on the basis of various scales including histomorphology, immunohistochemistry, fluorescent immunohybridization and genetics. Moreover, new categories such as high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations were added in the revised edition.

The initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma in the new guidelines are based on the recommendations in Lugano conference in 2014. These staging and response criteria can be applied to most types of lymphoma. In addition, fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) was formally incorporated into standard staging and used to assess response with the 5-point scale.

The prognosis system is also improved in the new guidelines. For example, National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) further stratified the levels of age and lactate dehydrogenase in terms of IPI, which can accurately predict the prognosis of patients with diffuse large B-cell lymphoma. Similarly, MIPI-c, combination of MIPI and

Ki-67, could better differentiate the prognosis of patients with mantle cell lymphoma. Notably, a novel prognosis model of NK/T cell lymphoma based on Chinese patients was established.

Classical strategies are highlighted consistently in the new guidelines. For example, the treatment of NK/T cell lymphoma with advanced stage should be based on chemotherapy with L-asparaginase or Pegaspargase (3). Autologous hematopoietic stem cell transplantation is still a preferred option of first-line consolidation therapy for patients with high-risk factors (4,5), especially for types including mantle cell lymphoma, lymphoblastic lymphoma and peripheral T-cell lymphoma. New drugs and therapies provide more options for the treatment of patients with relapsed/refractory disease (6,7). For example, immunosuppressants or Brentuximab Vedotin are used for the treatment of Hodgkin's lymphoma relapsed after autologous hematopoietic stem cell transplantation, ibrutinib is used for relapsed/refractory chronic lymphoblastic leukemia/small lymphoblastic lymphoma, and CAR-T therapy is used for relapsed/refractory diffuse large B-cell lymphoma.

In conclusion, the new guidelines provide a scale for precision and individualized treatment of lymphoma at various levels including diagnosis, staging, treatment and prognosis. The new guidelines will direct the clinical practice and promote the standardized diagnosis and treatment of lymphoma in China.

## Acknowledgements

None.

## Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

## References

1. Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. *J Hematol Oncol* 2019;12:22.
2. National Health Commission of the People's Republic of China. Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version). *Chin J Cancer Res* 2019;31:557-77.
3. Lin N, Song Y, Zheng W, et al. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. *J Hematol Oncol* 2013;6:44.
4. Xie Y, Zhang Y, Zheng W, et al. Outcomes of dose-adjusted Berlin-Frankfurt-Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma. *Med Oncol* 2015;32:110.
5. Wu M, Wang X, Xie Y, et al. Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas. *Int J Med Sci* 2018;15:867-74.
6. Song Y, Wu J, Chen X, et al. A single-arm, multi-center, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. *Clin Cancer Res* 2019. Epub ahead of print.
7. Ying Z, Huang XF, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy. *Nat Med* 2019;25:947-53.

**Cite this article as:** Liu W, Zhu J. Comments on *Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version)*. *Chin J Cancer Res* 2019;31(5):738-739. doi: 10.21147/j.issn.1000-9604.2019.05.02